Stephens analyst Scott Fidel lowered the firm’s price target on Humana to $570 from $575 and keeps an Overweight rating on the shares. While initially the company was comfortable earlier in the quarter that Medicare Advantage, MA, utilization trends were settling down, its Q3 results included continued upward pressure on MA MLR, the analyst tells investors. Humana’s Q3 adjusted EPS still came in above Street consensus and it continues to expect it will achieve its 2025 adjusted EPS target, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HUM:
- Humana ‘committed’ to 2025 adjusted EPS target of $37.00
- Humana backs FY23 adjusted EPS view to ‘at least’ $28.25, consensus $28.30
- ON Semiconductor, Array Technologies removed from ‘ US 1’ list at BofA
- Humana reports Q3 adjusted EPS $7.78, consensus $7.16
- Notable companies reporting before tomorrow’s open
